Visual acuity suppression

Visual acuity suppression is a reduction in the sharpness and resolving power of vision, making fine detail hard to distinguish.

As a drug effect it is acute and dose-proportional, fading as the substance wears off, which sets it apart from refractive disorders or pathological vision loss. It ranges from a mild softening of edges and text to a near-complete inability to read or identify faces at close range.

Visual acuity suppression is commonly reported across a wide range of psychoactive substance classes. It is most commonly induced at moderate to high doses under dissociatives such as ketamine and dextromethorphan, and under depressants like alcohol and alprazolam. It also appears under deliriants such as diphenhydramine and datura, and under cannabinoids including JWH-018 and 5F-PB-22.

Visual acuity suppression is felt as a diffuse softening of the visual field: edges blur, text becomes illegible, and faces lose definition, as though viewed through unfocused glass. Near tasks — reading, checking a phone — become effortful or impossible.

A sense of visual lag often accompanies it, where moving objects appear to trail behind themselves. Attending to the blur tends to heighten unease without restoring clarity. At high doses under dissociatives or deliriants it can deepen until familiar surroundings become unrecognizable.

Visual acuity suppression arises through different pathways depending on the drug class:

• Dissociatives — block NMDA receptors, disrupting the cortical processing that resolves fine visual detail.
• Depressants — enhance inhibitory signaling throughout the central nervous system; at sufficient doses this slows visual processing and reduces the contrast sensitivity required for sharp acuity.
• Deliriants — block muscarinic acetylcholine receptors, dilating the pupils and degrading depth of focus alongside broader impairment of visual processing.
• Cannabinoids — act on CB1 receptors, reducing the temporal precision of visual cortex responses.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how strongly, varies widely. Higher doses consistently deepen the effect across all implicated classes. Baseline visual health plays a role — those with existing refractive errors or low-light sensitivity tend to notice it earlier and more acutely.

Set and setting matter less here than with mood effects, though fatigue and poor ambient lighting amplify it. Prior exposure to a substance offers little protection; tolerance to visual suppression develops slowly, if at all, under most classes.